SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-058783
Filing Date
2021-11-12
Accepted
2021-11-12 17:15:29
Documents
44
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_actinium.htm   iXBRL 10-Q 802438
2 CERTIFICATION f10q0921ex31-1_actinium.htm EX-31.1 8448
3 CERTIFICATION f10q0921ex31-2_actinium.htm EX-31.2 8790
4 CERTIFICATION f10q0921ex32-1_actinium.htm EX-32.1 4304
5 CERTIFICATION f10q0921ex32-2_actinium.htm EX-32.2 4855
  Complete submission text file 0001213900-21-058783.txt   3346762

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atnm-20210930.xsd EX-101.SCH 35219
7 XBRL CALCULATION FILE atnm-20210930_cal.xml EX-101.CAL 24961
8 XBRL DEFINITION FILE atnm-20210930_def.xml EX-101.DEF 152272
9 XBRL LABEL FILE atnm-20210930_lab.xml EX-101.LAB 318914
10 XBRL PRESENTATION FILE atnm-20210930_pre.xml EX-101.PRE 165024
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_actinium_htm.xml XML 306694
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 211404848
SIC: 2834 Pharmaceutical Preparations